Core Insights - Cognition Therapeutics, Inc. announced strong therapeutic responses for zervimesine (CT1812) in patients with mild-to-moderate dementia with Lewy bodies (DLB), showing significant improvements across various measures compared to placebo [1][2][3] Study Results - The Phase 2 SHIMMER study involved 130 adults with mild-to-moderate DLB, demonstrating that zervimesine-treated participants scored 86% better on behavioral outcomes, 52% better on activities of daily living, 91% better on cognitive fluctuations, and 62% better on motor symptoms compared to placebo [2][3][6] - Zervimesine treatment resulted in fewer hallucinations, delusions, anxiety, and agitation in patients, which are common debilitating symptoms of DLB [2][4] - The study met its primary endpoint of safety and tolerability, with most treatment-related adverse events being mild or moderate [4][6] Mechanism of Action - Zervimesine is designed to penetrate the blood-brain barrier and selectively bind to the sigma-2 receptor complex, which is involved in regulating cellular processes disrupted by neurodegenerative disease drivers [8] Company Overview - Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and retina, with zervimesine as its lead candidate [9]
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC